[go: up one dir, main page]

WO2008135524A3 - Anthranilamides substitués et analogues, leur fabrication et utilisation en tant que médicaments - Google Patents

Anthranilamides substitués et analogues, leur fabrication et utilisation en tant que médicaments Download PDF

Info

Publication number
WO2008135524A3
WO2008135524A3 PCT/EP2008/055410 EP2008055410W WO2008135524A3 WO 2008135524 A3 WO2008135524 A3 WO 2008135524A3 EP 2008055410 W EP2008055410 W EP 2008055410W WO 2008135524 A3 WO2008135524 A3 WO 2008135524A3
Authority
WO
WIPO (PCT)
Prior art keywords
medicaments
analogues
manufacturing
substituted anthranilamides
anthranilamides
Prior art date
Application number
PCT/EP2008/055410
Other languages
English (en)
Other versions
WO2008135524A2 (fr
Inventor
Henning Priepke
Kai Gerlach
Wolfgang Wienen
Annette Schuler-Metz
Herbert Nar
Original Assignee
Boehringer Ingelheim Int
Henning Priepke
Kai Gerlach
Wolfgang Wienen
Annette Schuler-Metz
Herbert Nar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int, Henning Priepke, Kai Gerlach, Wolfgang Wienen, Annette Schuler-Metz, Herbert Nar filed Critical Boehringer Ingelheim Int
Publication of WO2008135524A2 publication Critical patent/WO2008135524A2/fr
Publication of WO2008135524A3 publication Critical patent/WO2008135524A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne de nouveaux prolinamides substitués de formule générale (I), D, M, A4, A5, R2, R3, R4 et R6 étant tels que définis dans la description, les tautomères, les énantiomères, les diastéréomères, les mélanges de ceux-ci et les sels de ceux-ci, en particulier les sels acceptables du point de vue pharmaceutique de ceux-ci avec des acides et des bases inorganiques ou organiques, qui ont des propriétés importantes.
PCT/EP2008/055410 2007-05-02 2008-05-02 Anthranilamides substitués et analogues, leur fabrication et utilisation en tant que médicaments WO2008135524A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07107357 2007-05-02
EP07107357.1 2007-05-02

Publications (2)

Publication Number Publication Date
WO2008135524A2 WO2008135524A2 (fr) 2008-11-13
WO2008135524A3 true WO2008135524A3 (fr) 2009-06-11

Family

ID=39885206

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/055410 WO2008135524A2 (fr) 2007-05-02 2008-05-02 Anthranilamides substitués et analogues, leur fabrication et utilisation en tant que médicaments

Country Status (1)

Country Link
WO (1) WO2008135524A2 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5524852B2 (ja) 2007-11-15 2014-06-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換アミド、それらの製造及び医薬品としての使用
PT3102576T (pt) 2014-02-03 2019-07-17 Vitae Pharmaceuticals Inc Inibidores de dihidropirrolopiridina de ror-gama
BR112017007460A2 (pt) 2014-10-14 2017-12-19 Vitae Pharmaceuticals Inc inibidores de di-hidropirrolopiridina de ror-gama
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
EP3078378B1 (fr) 2015-04-08 2020-06-24 Vaiomer Utilisation d'inhibiteurs du facteur xa destinés à réguler la glycémie
ES2856931T3 (es) 2015-08-05 2021-09-28 Vitae Pharmaceuticals Llc Moduladores de ROR-gamma
AU2016355710B2 (en) 2015-11-20 2021-03-25 Vitae Pharmaceuticals, Llc Modulators of ROR-gamma
TWI757266B (zh) 2016-01-29 2022-03-11 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
WO2017192304A1 (fr) * 2016-05-02 2017-11-09 Inception 1, Inc. Arylcarboxamides et leurs utilisations
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
WO2019018975A1 (fr) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. Inhibiteurs de ror gamma
CN115716826A (zh) 2017-07-24 2023-02-28 生命医药有限责任公司 RORγ的抑制剂
US20190270733A1 (en) * 2018-03-01 2019-09-05 Reaction Biology Corp. Quinoline and Isoquinoline Based HDAC Inhibitors and Methods of Use Thereof
WO2021257863A1 (fr) 2020-06-19 2021-12-23 Incyte Corporation Composés de pyrrolotriazine utilisés en tant qu'inhibiteurs de v617f de jak2
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
CR20230057A (es) 2020-07-02 2023-08-15 Incyte Corp Compuestos tríciclicos de urea como inhibidores de jak2 v617f
WO2022006456A1 (fr) 2020-07-02 2022-01-06 Incyte Corporation Composés de pyridone tricyclique en tant qu'inhibiteurs de v617f de jak2
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
WO2022140231A1 (fr) 2020-12-21 2022-06-30 Incyte Corporation Composés de déazaguanine utilisés en tant qu'inhibiteurs de v617f de jak2
EP4298099A1 (fr) 2021-02-25 2024-01-03 Incyte Corporation Lactames spirocycliques utilisés comme inhibiteurs du v617f de jak2
MX2024011378A (es) 2022-03-17 2024-09-23 Incyte Corp Compuestos de urea triciclica como inhibidores de la variante v617f de la cinasa de janus 2 (jak2).

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999032477A1 (fr) * 1997-12-19 1999-07-01 Schering Aktiengesellschaft Derives d'$i(ortho)-anthranilamide comme anticoagulants
WO2002042270A1 (fr) * 2000-11-22 2002-05-30 Yamanouchi Pharmaceutical Co., Ltd. Derives de benzene substitues ou leurs sels
JP2004210716A (ja) * 2002-12-27 2004-07-29 Dai Ichi Seiyaku Co Ltd ジアミド誘導体

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999032477A1 (fr) * 1997-12-19 1999-07-01 Schering Aktiengesellschaft Derives d'$i(ortho)-anthranilamide comme anticoagulants
WO2002042270A1 (fr) * 2000-11-22 2002-05-30 Yamanouchi Pharmaceutical Co., Ltd. Derives de benzene substitues ou leurs sels
EP1336605A1 (fr) * 2000-11-22 2003-08-20 Yamanouchi Pharmaceutical Co. Ltd. Derives de benzene substitues ou leurs sels
JP2004210716A (ja) * 2002-12-27 2004-07-29 Dai Ichi Seiyaku Co Ltd ジアミド誘導体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE HCAPLUS [online] ACS; XP002502775, retrieved from STN Database accession no. 141:156930 (DN) *
KOCHANNY ET AL: "Substituted thiophene-anthranilamides as potent inhibitors of human factor Xa", BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER SCIENCE LTD, GB, vol. 15, no. 5, 31 January 2007 (2007-01-31), pages 2127 - 2146, XP005867178, ISSN: 0968-0896 *

Also Published As

Publication number Publication date
WO2008135524A2 (fr) 2008-11-13

Similar Documents

Publication Publication Date Title
WO2008135524A3 (fr) Anthranilamides substitués et analogues, leur fabrication et utilisation en tant que médicaments
WO2008117241A3 (fr) Dérivés de thiazolidine
WO2009022311A3 (fr) Dérivés du 1,2-diamido-éthylène
WO2009016560A3 (fr) Dérivés de trans-3-aza-bicyclo[3.1.0]hexane
WO2009077443A3 (fr) Azolylméthyloxiranes, leur utilisation et agents les contenant
IL184526A0 (en) Substituted aminomethylene sulphonamides, production and use thereof as medicaments
WO2008101187A3 (fr) Pro-médicaments d'antagonistes opioïdes phénoliques périphériques
WO2009077500A3 (fr) Azolylméthyloxiranes, leur utilisation et agents les contenant
WO2007061360A3 (fr) Nouveau composes
WO2008153159A1 (fr) Composé aminé et son utilisation pharmaceutique
GEP20125487B (en) Organic compounds and their use
WO2009040730A3 (fr) Pyrrolidines et pipéridines en tant qu'antagonistes du récepteur de l'orexine
MY153921A (en) Aminopyrazole derivatives
WO2009003999A3 (fr) Nouveaux composés chimiques
WO2007112014A3 (fr) Nouvelles combinaisons thérapeutiques pour le traitement de la dépression
TW200626598A (en) Pyrrazolo-pyrimidine derivatives
IL210549A (en) Pipedrine - Quinocosalin-Mediated Conjugated Drugs
MY153763A (en) Quinazolinedione derivatives, preparation thereof and therapeutic uses thereof
UA96753C2 (ru) Лекарственное средство, которое содержит фторхинолоны
WO2009021868A3 (fr) Nouveaux dérivés amides de la pipérazine
WO2007083060A3 (fr) Derives de chalcone a activite antimitotique
TW200738627A (en) Trialkylsilyl-indoles
TW200637842A (en) Substituted 4-phenyltetrahydroisoquinolines, process for their preparation, their use as a medicament and medicament comprising them
TW200744612A (en) New combination
WO2008119720A8 (fr) Dérivés de 1-(1-cyclobutyl-4-piperidinyl)-1,3-dihydro-2h-benzimidazol-2-one qui ont une activité sur le récepteur m1 et leur utilisation en médecine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08749982

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08749982

Country of ref document: EP

Kind code of ref document: A2